Pfizer and Astellas Announce Positive Top-Line Results from Phase 3 PROSPER Trial of XTANDI (enzalutamide) in Patients with Non-Metastatic Castration-Resistant Prostate Cancer
Enzalutamide is the first androgen receptor-inhibitor to demonstrate a statistically significant improvement in metastasis-free survival (MFS) in this patient population in a randomized, controlled clinical trial
NEW YORK and TOKYO, Sept. 14, 2017 -- (H... Biopharmaceuticals, Oncology Astellas Pharma, Pfizer, XTANDI, enzalutamide, prostate cancer
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Clinical Trials | Pfizer | Pharmaceuticals | Prostate Cancer | Statistics